Business Wire

PHYTOCANN-GROUP

17.1.2023 11:12:36 CET | Business Wire | Press release

Share
FOLLOWING THE COUNCIL OF STATE'S RULING, ONE OF CBD.FR'S CUSTOMERS WILL WIN THEIR OWN WEIGHT IN CBD FLOWERS

On December 29, 2022, the Council of State announced the definitive authorization of the sale of CBD flowers in France. To celebrate the end of a protracted battle, CBD.fr will be offering one of its customers buying a product from its website, CBD.fr, between January 17 and April 20, 2023, the chance to win their own weight in CBD flowers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005347/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gagne ton poids en weed (Photo: CBD.fr)

Following the purchase of CBD.fr in October 2022 by Phytocann Group and the reversal of the ban, CBD.fr can now devote itself fully to developing on national territory.

Current leader in online CBD sales, with more than 500 products available, CBD.fr brings together the most well-known brands in France in varied areas such as: CBD oils, CBD flowers, CBD resins, CBD for animals, and more. At the same time, CBD.fr is developing its franchise network with the goal of opening 400 shops across France by 2026. Since January 1, 18 CBD Shops have already started opening.

"This decision by the Council of State does a great deal to reassure our entire industry. It marks a huge step forward and, to celebrate this, we are organizing the hottest competition ever held in the cannabis world. Purchases made from January 1 onward will be eligible. In addition to the contest, we also want to raise awareness and contribute, in our own way, to the purchasing power of French people in our sector by offering high-quality products that are affordable for all. There is also a social aspect that we are all concerned about."

Alexandre Lacarré, Founder of Phytocann Group

April 20, 2023, the day on which the winner will be announced, is not just a random date. Find out who has won at 4.20 pm on 420 Day, or International Cannabis Day!

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005347/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

Elliptic Announces Circle’s Participation in Agentic Design Partner Program9.7.2026 14:15:00 CEST | Press release

Following investment from Circle Ventures, the corporate venture arm of Circle Elliptic, the global leader in digital asset intelligence, today announced that an affiliate of Circle Internet Group, Inc. (‘Circle’) (NYSE:CRCL) has joined its Agentic Design Partner Program, bringing together infrastructure providers, compliance teams, and technology leaders to help shape compliance solutions for autonomous, AI-driven financial activity. This momentum follows an investment from Circle Ventures, the corporate venture arm of Circle, and builds on a longstanding collaboration between the companies. Circle has been an Elliptic customer for multiple years and has expanded its use of Elliptic’s compliance capabilities across a range of digital asset initiatives. As stablecoins, tokenized assets, and AI-powered applications become increasingly integrated into financial services, new compliance challenges are emerging. Elliptic’s agentic compliance layer addresses these challenges by combining un

Russell Investments Announces New Long-Term Owners9.7.2026 14:00:00 CEST | Press release

An investor consortium led by B Capital and including CalPERS will provide long-term capital to expandRussell Investments’ client capabilities and accelerate innovation Russell Investments, the global investment solutions provider, today announced that an investor consortium (the “Investor Consortium”) led by B Capital, a global multi-stage investment firm, and including California Public Employees' Retirement System ("CalPERS"), has agreed to acquire the firm from TA Associates (“TA”) and Reverence Capital Partners (“RCP”). The transaction comes as Russell Investments marks over $416 billion in global assets under management (AUM) and has experienced more than 15% organic growth over the past two years. Russell Investments has been a trusted, independent partner to its clients for over 90 years. Its open-architecture model delivers portfolio solutions that source from the full landscape of the asset management industry across public and private markets. With a shared vision for the co

Esri and Global Partners Release HydroSHEDS v2 for the Americas9.7.2026 14:00:00 CEST | Press release

Next-Generation Hydrographic Framework Delivers Unprecedented Detail for Watershed and River Network Analysis Esri and its global partners have released HydroSHEDS v2, providing high-resolution hydrographic data for North, Central, and South America. Developed with World Wildlife Fund in the US, McGill University and Confluvio Consulting in Canada, and the German Aerospace Center (DLR), the initiative reflects global collaboration in hydrologic science and geospatial technology. HydroSHEDS v2 leverages TanDEM-X elevation data and Arc Hydro workflows to deliver more accurate drainage networks, watershed boundaries, and hydrologic connectivity. The datasets support applications such as flood risk assessments, climate resilience studies, systematic conservation planning, water resource management, and environmental decision-making. HydroSHEDS v2 datasets are available through ArcGIS Living Atlas, with additional global releases planned as part of a phased rollout. Esri has made HydroSHEDS

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye